Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

CD138 plasma cells may predict brain metastasis recurrence following resection and stereotactic radiosurgery.

Soike MH, Logue J, Qasem S, Hughes RT, McTyre E, Su J, Triozzi P, Bendandi M, Lo HW, Ahmed T, O'Neill SS, Debinski W, Pasche B, Watabe K, Miller LD, Chan MD, Ruiz J.

Sci Rep. 2019 Oct 7;9(1):14385. doi: 10.1038/s41598-019-50298-7.

2.

Characterization of Ablation Thresholds for 3D-Cultured Patient-Derived Glioma Stem Cells in Response to High-Frequency Irreversible Electroporation.

Ivey JW, Wasson EM, Alinezhadbalalami N, Kanitkar A, Debinski W, Sheng Z, Davalos RV, Verbridge SS.

Research (Wash D C). 2019 Apr 28;2019:8081315. doi: 10.34133/2019/8081315. eCollection 2019.

3.

TGLI1 transcription factor mediates breast cancer brain metastasis via activating metastasis-initiating cancer stem cells and astrocytes in the tumor microenvironment.

Sirkisoon SR, Carpenter RL, Rimkus T, Doheny D, Zhu D, Aguayo NR, Xing F, Chan M, Ruiz J, Metheny-Barlow LJ, Strowd R, Lin J, Regua AT, Arrigo A, Anguelov M, Pasche B, Debinski W, Watabe K, Lo HW.

Oncogene. 2019 Aug 28. doi: 10.1038/s41388-019-0959-3. [Epub ahead of print]

PMID:
31462709
4.

P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment.

Mao C, Li F, Zhao Y, Debinski W, Ming X.

Theranostics. 2018 Nov 29;8(22):6274-6290. doi: 10.7150/thno.29580. eCollection 2018.

5.

Receptor-Targeted Glial Brain Tumor Therapies.

Sharma P, Debinski W.

Int J Mol Sci. 2018 Oct 25;19(11). pii: E3326. doi: 10.3390/ijms19113326. Review.

6.

When better still might not be good enough.

Debinski W.

Transl Cancer Res. 2017 Oct;6(Suppl 7):S1244-S1247. doi: 10.21037/tcr.2017.09.40. No abstract available.

7.

Glioblastoma radiomics: can genomic and molecular characteristics correlate with imaging response patterns?

Soike MH, McTyre ER, Shah N, Puchalski RB, Holmes JA, Paulsson AK, Miller LD, Cramer CK, Lesser GJ, Strowd RE, Hinson WH, Mott RT, Johnson AJ, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD.

Neuroradiology. 2018 Oct;60(10):1043-1051. doi: 10.1007/s00234-018-2060-y. Epub 2018 Aug 10.

PMID:
30094640
8.

Hypoxia-inducible factor 2α: a novel target in gliomas.

Renfrow JJ, Soike MH, Debinski W, Ramkissoon SH, Mott RT, Frenkel MB, Sarkaria JN, Lesser GJ, Strowd RE.

Future Med Chem. 2018 Sep 1;10(18):2227-2236. doi: 10.4155/fmc-2018-0163. Epub 2018 Aug 9. Review.

9.

P-glycoprotein targeted and near-infrared light-guided depletion of chemoresistant tumors.

Mao C, Zhao Y, Li F, Li Z, Tian S, Debinski W, Ming X.

J Control Release. 2018 Sep 28;286:289-300. doi: 10.1016/j.jconrel.2018.08.005. Epub 2018 Aug 4.

10.

Loss of XIST in Breast Cancer Activates MSN-c-Met and Reprograms Microglia via Exosomal miRNA to Promote Brain Metastasis.

Xing F, Liu Y, Wu SY, Wu K, Sharma S, Mo YY, Feng J, Sanders S, Jin G, Singh R, Vidi PA, Tyagi A, Chan MD, Ruiz J, Debinski W, Pasche BC, Lo HW, Metheny-Barlow LJ, D'Agostino RB Jr, Watabe K.

Cancer Res. 2018 Aug 1;78(15):4316-4330. doi: 10.1158/0008-5472.CAN-18-1102. Epub 2018 Jul 19.

11.

miR-30 disrupts senescence and promotes cancer by targeting both p16INK4A and DNA damage pathways.

Su W, Hong L, Xu X, Huang S, Herpai D, Li L, Xu Y, Truong L, Hu WY, Wu X, Xiao C, Zhang W, Han J, Debinski W, Xiang R, Sun P.

Oncogene. 2018 Oct;37(42):5618-5632. doi: 10.1038/s41388-018-0358-1. Epub 2018 Jun 15.

12.

Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44.

Rimkus TK, Carpenter RL, Sirkisoon S, Zhu D, Pasche BC, Chan MD, Lesser GJ, Tatter SB, Watabe K, Debinski W, Lo HW.

Cancer Res. 2018 May 15;78(10):2589-2600. doi: 10.1158/0008-5472.CAN-17-2933. Epub 2018 Feb 20.

13.

Maximizing Local Access to Therapeutic Deliveries in Glioblastoma. Part I: Targeted Cytotoxic Therapy.

Debinski W, Priebe W, Tatter SB.

In: De Vleeschouwer S, editor. Glioblastoma [Internet]. Brisbane (AU): Codon Publications; 2017 Sep 27. Chapter 17.

14.

Combined inhibition of AKT and HSF1 suppresses breast cancer stem cells and tumor growth.

Carpenter RL, Sirkisoon S, Zhu D, Rimkus T, Harrison A, Anderson A, Paw I, Qasem S, Xing F, Liu Y, Chan M, Metheny-Barlow L, Pasche BC, Debinski W, Watabe K, Lo HW.

Oncotarget. 2017 May 22;8(43):73947-73963. doi: 10.18632/oncotarget.18166. eCollection 2017 Sep 26.

15.

Use of non-ionizing electromagnetic fields for the treatment of cancer.

Jimenez H, Blackman C, Lesser G, Debinski W, Chan M, Sharma S, Watabe K, Lo HW, Thomas A, Godwin D, Blackstock W, Mudry A, Posey J, O'Connor R, Brezovich I, Bonin K, Kim-Shapiro D, Barbault A, Pasche B.

Front Biosci (Landmark Ed). 2018 Jan 1;23:284-297. Review.

PMID:
28930547
16.

Peptide-based PET imaging of the tumor restricted IL13RA2 biomarker.

Sai KKS, Sattiraju A, Almaguel FG, Xuan A, Rideout S, Krishnaswamy RS, Zhang J, Herpai DM, Debinski W, Mintz A.

Oncotarget. 2017 Mar 24;8(31):50997-51007. doi: 10.18632/oncotarget.16549. eCollection 2017 Aug 1.

17.

Novel Molecular Multilevel Targeted Antitumor Agents.

Sonawane P, Choi YA, Pandya H, Herpai DM, Fokt I, Priebe W, Debinski W.

Cancer Transl Med. 2017 May-Jun;3(3):69-79. doi: 10.4103/ctm.ctm_12_17. Epub 2017 Jun 8.

18.

Enhancing Irreversible Electroporation by Manipulating Cellular Biophysics with a Molecular Adjuvant.

Ivey JW, Latouche EL, Richards ML, Lesser GJ, Debinski W, Davalos RV, Verbridge SS.

Biophys J. 2017 Jul 25;113(2):472-480. doi: 10.1016/j.bpj.2017.06.014.

19.

IL13RA2 targeted alpha particle therapy against glioblastomas.

Sattiraju A, Solingapuram Sai KK, Xuan A, Pandya DN, Almaguel FG, Wadas TJ, Herpai DM, Debinski W, Mintz A.

Oncotarget. 2017 Jun 27;8(26):42997-43007. doi: 10.18632/oncotarget.17792.

20.

Expression and activity of the urokinase plasminogen activator system in canine primary brain tumors.

Rossmeisl JH, Hall-Manning K, Robertson JL, King JN, Davalos RV, Debinski W, Elankumaran S.

Onco Targets Ther. 2017 Apr 12;10:2077-2085. doi: 10.2147/OTT.S132964. eCollection 2017.

21.

Outcomes for Anaplastic Glioma Treated With Radiation Therapy With or Without Concurrent Temozolomide.

McTyre E, Lucas JT, Helis C, Farris M, Soike M, Mott R, Laxton AW, Tatter SB, Lesser GJ, Strowd RE, Lo HW, Debinski W, Chan MD.

Am J Clin Oncol. 2018 Aug;41(8):813-819. doi: 10.1097/COC.0000000000000380.

PMID:
28301347
22.

Selection of a Novel Aptamer Against Vitronectin Using Capillary Electrophoresis and Next Generation Sequencing.

Stuart CH, Riley KR, Boyacioglu O, Herpai DM, Debinski W, Qasem S, Marini FC, Colyer CL, Gmeiner WH.

Mol Ther Nucleic Acids. 2016 Nov 15;5(11):e386. doi: 10.1038/mtna.2016.91.

23.

Impact of timing of radiotherapy in patients with newly diagnosed glioblastoma.

Randolph DM 2nd, McTyre ER, Paulsson AK, Holmes JA, Hinson WH, Lesser GJ, Strowd R, Lo HW, Laxton AW, Tatter SB, Debinski W, Chan MD.

Clin Neurol Neurosurg. 2016 Dec;151:73-78. doi: 10.1016/j.clineuro.2016.10.012. Epub 2016 Oct 22.

PMID:
27816029
24.

Simultaneous targeting of Eph receptors in glioblastoma.

Ferluga S, Tomé CM, Herpai DM, D'Agostino R, Debinski W.

Oncotarget. 2016 Sep 13;7(37):59860-59876. doi: 10.18632/oncotarget.10978.

25.

Canine Butterfly Glioblastomas: A Neuroradiological Review.

Rossmeisl JH, Clapp K, Pancotto TE, Emch S, Robertson JL, Debinski W.

Front Vet Sci. 2016 May 19;3:40. doi: 10.3389/fvets.2016.00040. eCollection 2016.

26.

The applications of the novel polymeric fluoropyrimidine F10 in cancer treatment: current evidence.

Gmeiner WH, Debinski W, Milligan C, Caudell D, Pardee TS.

Future Oncol. 2016 Sep;12(17):2009-20. doi: 10.2217/fon-2016-0091. Epub 2016 Jun 9. Review.

27.

Pseudo progression identification of glioblastoma with dictionary learning.

Zhang J, Yu H, Qian X, Liu K, Tan H, Yang T, Wang M, Li KC, Chan MD, Debinski W, Paulsson A, Wang G, Zhou X.

Comput Biol Med. 2016 Jun 1;73:94-101. doi: 10.1016/j.compbiomed.2016.03.027. Epub 2016 Apr 1.

28.

Local control of brain metastases after stereotactic radiosurgery: the impact of whole brain radiotherapy and treatment paradigm.

Hughes RT, Black PJ, Page BR, Lucas JT Jr, Qasem SA, Watabe K, Ruiz J, Laxton AW, Tatter SB, Debinski W, Chan MD.

J Radiosurg SBRT. 2016;4(2):89-96.

29.

Treatment of brain metastases of lung cancer in the era of precision medicine.

Haughton ME, Chan MD, Watabe K, Bonomi M, Debinski W, Lesser GJ, Ruiz J.

Front Biosci (Elite Ed). 2016 Jan 1;8:219-32.

PMID:
26709658
30.

Frame-Based Stereotactic Biopsy of Canine Brain Masses: Technique and Clinical Results in 26 Cases.

Rossmeisl JH, Andriani RT, Cecere TE, Lahmers K, LeRoith T, Zimmerman KL, Gibo D, Debinski W.

Front Vet Sci. 2015 Jul 27;2:20. doi: 10.3389/fvets.2015.00020. eCollection 2015.

31.

Neurosurgical Techniques for Disruption of the Blood-Brain Barrier for Glioblastoma Treatment.

Rodriguez A, Tatter SB, Debinski W.

Pharmaceutics. 2015 Aug 3;7(3):175-87. doi: 10.3390/pharmaceutics7030175. Review.

32.

Genomic predictors of patterns of progression in glioblastoma and possible influences on radiation field design.

Holmes JA, Paulsson AK, Page BR, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD.

J Neurooncol. 2015 Sep;124(3):447-53. doi: 10.1007/s11060-015-1858-2. Epub 2015 Jul 18.

33.

The gain-of-function GLI1 transcription factor TGLI1 enhances expression of VEGF-C and TEM7 to promote glioblastoma angiogenesis.

Carpenter RL, Paw I, Zhu H, Sirkisoon S, Xing F, Watabe K, Debinski W, Lo HW.

Oncotarget. 2015 Sep 8;6(26):22653-65.

34.

Impact of systemic targeted agents on the clinical outcomes of patients with brain metastases.

Johnson AG, Ruiz J, Hughes R, Page BR, Isom S, Lucas JT, McTyre ER, Houseknecht KW, Ayala-Peacock DN, Bourland DJ, Hinson WH, Laxton AW, Tatter SB, Debinski W, Watabe K, Chan MD.

Oncotarget. 2015 Aug 7;6(22):18945-55.

35.

Mechanisms regulating glioma invasion.

Paw I, Carpenter RC, Watabe K, Debinski W, Lo HW.

Cancer Lett. 2015 Jun 28;362(1):1-7. doi: 10.1016/j.canlet.2015.03.015. Epub 2015 Mar 18. Review.

36.

Ephs and Ephrins in malignant gliomas.

Ferluga S, Debinski W.

Growth Factors. 2014 Dec;32(6):190-201. doi: 10.3109/08977194.2014.985787. Epub 2014 Nov 24. Review.

37.

Comparison of clinical outcomes and genomic characteristics of single focus and multifocal glioblastoma.

Paulsson AK, Holmes JA, Peiffer AM, Miller LD, Liu W, Xu J, Hinson WH, Lesser GJ, Laxton AW, Tatter SB, Debinski W, Chan MD.

J Neurooncol. 2014 Sep;119(2):429-35. doi: 10.1007/s11060-014-1515-1. Epub 2014 Jul 3.

38.

Selective anti-tumor activity of the novel fluoropyrimidine polymer F10 towards G48a orthotopic GBM tumors.

Gmeiner WH, Lema-Tome C, Gibo D, Jennings-Gee J, Milligan C, Debinski W.

J Neurooncol. 2014 Feb;116(3):447-54. doi: 10.1007/s11060-013-1321-1. Epub 2013 Dec 18.

39.

Invited review--neuroimaging response assessment criteria for brain tumors in veterinary patients.

Rossmeisl JH Jr, Garcia PA, Daniel GB, Bourland JD, Debinski W, Dervisis N, Klahn S.

Vet Radiol Ultrasound. 2014 Mar-Apr;55(2):115-32. doi: 10.1111/vru.12118. Epub 2013 Nov 13. Review.

40.

Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.

Baiz D, Hassan S, Choi YA, Flores A, Karpova Y, Yancey D, Pullikuth A, Sui G, Sadelain M, Debinski W, Kulik G.

Neoplasia. 2013 Oct;15(10):1172-83.

41.

New agents for targeting of IL-13RA2 expressed in primary human and canine brain tumors.

Debinski W, Dickinson P, Rossmeisl JH, Robertson J, Gibo DM.

PLoS One. 2013 Oct 16;8(10):e77719. doi: 10.1371/journal.pone.0077719. eCollection 2013.

42.

Biological and structural characterization of glycosylation on ephrin-A1, a preferred ligand for EphA2 receptor tyrosine kinase.

Ferluga S, Hantgan R, Goldgur Y, Himanen JP, Nikolov DB, Debinski W.

J Biol Chem. 2013 Jun 21;288(25):18448-57. doi: 10.1074/jbc.M113.464008. Epub 2013 May 9.

43.

Limited margins using modern radiotherapy techniques does not increase marginal failure rate of glioblastoma.

Paulsson AK, McMullen KP, Peiffer AM, Hinson WH, Kearns WT, Johnson AJ, Lesser GJ, Ellis TL, Tatter SB, Debinski W, Shaw EG, Chan MD.

Am J Clin Oncol. 2014 Apr;37(2):177-81. doi: 10.1097/COC.0b013e318271ae03.

44.

A novel ligand delivery system to non-invasively visualize and therapeutically exploit the IL13Rα2 tumor-restricted biomarker.

Nguyen V, Conyers JM, Zhu D, Gibo DM, Hantgan RR, Larson SM, Debinski W, Mintz A.

Neuro Oncol. 2012 Oct;14(10):1239-53. Epub 2012 Sep 5.

45.

EphrinA1 is released in three forms from cancer cells by matrix metalloproteases.

Beauchamp A, Lively MO, Mintz A, Gibo D, Wykosky J, Debinski W.

Mol Cell Biol. 2012 Aug;32(16):3253-64. doi: 10.1128/MCB.06791-11. Epub 2012 Jun 11.

46.

Toward intracellular targeted delivery of cancer therapeutics: progress and clinical outlook for brain tumor therapy.

Pandya H, Debinski W.

BioDrugs. 2012 Aug 1;26(4):235-44. doi: 10.2165/11631600-000000000-00000.

47.

Structural and functional characterization of monomeric EphrinA1 binding site to EphA2 receptor.

Lema Tomé CM, Palma E, Ferluga S, Lowther WT, Hantgan R, Wykosky J, Debinski W.

J Biol Chem. 2012 Apr 20;287(17):14012-22. doi: 10.1074/jbc.M111.311670. Epub 2012 Feb 23.

48.

IL-13Rα2-Targeted Therapy Escapees: Biologic and Therapeutic Implications.

Nguyen V, Conyers JM, Zhu D, Gibo DM, Dorsey JF, Debinski W, Mintz A.

Transl Oncol. 2011 Dec;4(6):390-400. Epub 2011 Dec 1.

49.

Ephs and ephrins in cancer: ephrin-A1 signalling.

Beauchamp A, Debinski W.

Semin Cell Dev Biol. 2012 Feb;23(1):109-15. doi: 10.1016/j.semcdb.2011.10.019. Epub 2011 Oct 25. Review.

50.

An interleukin 13 receptor α 2-specific peptide homes to human Glioblastoma multiforme xenografts.

Pandya H, Gibo DM, Garg S, Kridel S, Debinski W.

Neuro Oncol. 2012 Jan;14(1):6-18. doi: 10.1093/neuonc/nor141. Epub 2011 Sep 26.

Supplemental Content

Loading ...
Support Center